APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Viral Conjunctivitis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Viral Conjunctivitis Drugs Market Outlook and Growth Opportunities 2026

Report ID 174046460422 December 2025193 pages

Choose your research edition.

Industry ResearchViral Conjunctivitis Drugs Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Viral Conjunctivitis Drugs Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Viral Conjunctivitis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Viral Conjunctivitis Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Viral Conjunctivitis Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Viral Conjunctivitis Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Viral Conjunctivitis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Viral Conjunctivitis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Viral Conjunctivitis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Viral Conjunctivitis Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Viral Conjunctivitis Drugs market include Takeda, Novartis, Panoptes Pharma, NovaBay Pharmaceuticals, NicOx, NanoViricides, Allergan and Adenovir Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Viral Conjunctivitis Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Viral Conjunctivitis Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Viral Conjunctivitis Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Viral Conjunctivitis Drugs market.

Viral Conjunctivitis Drugs Segment by Company

Takeda

Novartis

Panoptes Pharma

NovaBay Pharmaceuticals

NicOx

NanoViricides

Allergan

Adenovir Pharma

Viral Conjunctivitis Drugs Segment by Type

FST-100

APD—209

Viral Conjunctivitis Drugs Segment by Application

Hospitals

ASCs

Others

Viral Conjunctivitis Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Viral Conjunctivitis Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Viral Conjunctivitis Drugs key companies, revenue, market share, and recent developments.

3. To split the Viral Conjunctivitis Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Viral Conjunctivitis Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Viral Conjunctivitis Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Viral Conjunctivitis Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Conjunctivitis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Viral Conjunctivitis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Conjunctivitis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Viral Conjunctivitis Drugs industry.

Chapter 3: Detailed analysis of Viral Conjunctivitis Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Viral Conjunctivitis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Viral Conjunctivitis Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Viral Conjunctivitis Drugs Industry Trends Table 2. Viral Conjunctivitis Drugs Industry Drivers Table 3. Viral Conjunctivitis Drugs Industry Opportunities and Challenges Table 4. Viral Conjunctivitis Drugs Industry Restraints Table 5. Global Viral Conjunctivitis Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Viral Conjunctivitis Drugs Revenue Share by Company (2021-2026) Table 7. Global Viral Conjunctivitis Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Viral Conjunctivitis Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Viral Conjunctivitis Drugs Company, Product Type & Application Table 10. Global Viral Conjunctivitis Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Viral Conjunctivitis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of FST-100 Table 15. Significant Companies of APD—209 Table 16. Global Viral Conjunctivitis Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Viral Conjunctivitis Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Viral Conjunctivitis Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Viral Conjunctivitis Drugs Sales Value Share by Type (2021-2026) Table 20. Global Viral Conjunctivitis Drugs Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospitals Table 22. Significant Companies of ASCs Table 23. Significant Companies of Others Table 24. Global Viral Conjunctivitis Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Viral Conjunctivitis Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Viral Conjunctivitis Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Viral Conjunctivitis Drugs Sales Value Share by Application (2021-2026) Table 28. Global Viral Conjunctivitis Drugs Sales Value Share by Application (2027-2032) Table 29. Global Viral Conjunctivitis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Viral Conjunctivitis Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Viral Conjunctivitis Drugs Sales Value Share by Region (2021-2026) Table 32. Global Viral Conjunctivitis Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Viral Conjunctivitis Drugs Sales Value Share by Region (2027-2032) Table 34. Global Viral Conjunctivitis Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Viral Conjunctivitis Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Viral Conjunctivitis Drugs Sales Value Market Share by Country (2021-2026) Table 37. Global Viral Conjunctivitis Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Viral Conjunctivitis Drugs Sales Value Market Share by Country (2027-2032) Table 39. Takeda Company Information Table 40. Takeda Business Overview Table 41. Takeda Viral Conjunctivitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Takeda Viral Conjunctivitis Drugs Product Portfolio Table 43. Takeda Recent Development Table 44. Novartis Company Information Table 45. Novartis Business Overview Table 46. Novartis Viral Conjunctivitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Novartis Viral Conjunctivitis Drugs Product Portfolio Table 48. Novartis Recent Development Table 49. Panoptes Pharma Company Information Table 50. Panoptes Pharma Business Overview Table 51. Panoptes Pharma Viral Conjunctivitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Panoptes Pharma Viral Conjunctivitis Drugs Product Portfolio Table 53. Panoptes Pharma Recent Development Table 54. NovaBay Pharmaceuticals Company Information Table 55. NovaBay Pharmaceuticals Business Overview Table 56. NovaBay Pharmaceuticals Viral Conjunctivitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. NovaBay Pharmaceuticals Viral Conjunctivitis Drugs Product Portfolio Table 58. NovaBay Pharmaceuticals Recent Development Table 59. NicOx Company Information Table 60. NicOx Business Overview Table 61. NicOx Viral Conjunctivitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. NicOx Viral Conjunctivitis Drugs Product Portfolio Table 63. NicOx Recent Development Table 64. NanoViricides Company Information Table 65. NanoViricides Business Overview Table 66. NanoViricides Viral Conjunctivitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. NanoViricides Viral Conjunctivitis Drugs Product Portfolio Table 68. NanoViricides Recent Development Table 69. Allergan Company Information Table 70. Allergan Business Overview Table 71. Allergan Viral Conjunctivitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Allergan Viral Conjunctivitis Drugs Product Portfolio Table 73. Allergan Recent Development Table 74. Adenovir Pharma Company Information Table 75. Adenovir Pharma Business Overview Table 76. Adenovir Pharma Viral Conjunctivitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Adenovir Pharma Viral Conjunctivitis Drugs Product Portfolio Table 78. Adenovir Pharma Recent Development Table 79. Research Programs/Design for This Report Table 80. Authors List of This Report Table 81. Secondary Sources Table 82. Primary Sources List of Figures Figure 1. Viral Conjunctivitis Drugs Product Image Figure 2. Global Viral Conjunctivitis Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Viral Conjunctivitis Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Viral Conjunctivitis Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. FST-100 Image Figure 8. APD—209 Image Figure 9. Global Viral Conjunctivitis Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Viral Conjunctivitis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Viral Conjunctivitis Drugs Sales Value Share by Type (2021-2032) Figure 12. Hospitals Image Figure 13. ASCs Image Figure 14. Others Image Figure 15. Global Viral Conjunctivitis Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Viral Conjunctivitis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Viral Conjunctivitis Drugs Sales Value Share by Application (2021-2032) Figure 18. Global Viral Conjunctivitis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Viral Conjunctivitis Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Viral Conjunctivitis Drugs Sales Value (2021-2032) & (US$ Million) Figure 21. North America Viral Conjunctivitis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Viral Conjunctivitis Drugs Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Viral Conjunctivitis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Viral Conjunctivitis Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Viral Conjunctivitis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Viral Conjunctivitis Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. South America Viral Conjunctivitis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Viral Conjunctivitis Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Viral Conjunctivitis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • FST-100
  • APD—209
Applications
  • Hospitals
  • ASCs
  • Others
Companies covered
  • Takeda
  • Novartis
  • Panoptes Pharma
  • NovaBay Pharmaceuticals
  • NicOx
  • NanoViricides
  • Allergan
  • Adenovir Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Viral Conjunctivitis Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Viral Conjunctivitis Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Viral Conjunctivitis Drugs Market Dynamics
  1. 2.1 Viral Conjunctivitis Drugs Industry Trends
  2. 2.2 Viral Conjunctivitis Drugs Industry Drivers
  3. 2.3 Viral Conjunctivitis Drugs Industry Opportunities and Challenges
  4. 2.4 Viral Conjunctivitis Drugs Industry Restraints
3 Viral Conjunctivitis Drugs Market by Company
  1. 3.1 Global Viral Conjunctivitis Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Viral Conjunctivitis Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Viral Conjunctivitis Drugs Company Ranking (2024-2026)
  4. 3.4 Global Viral Conjunctivitis Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Viral Conjunctivitis Drugs Company Product Type and Application
  6. 3.6 Global Viral Conjunctivitis Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Viral Conjunctivitis Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Viral Conjunctivitis Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Viral Conjunctivitis Drugs Market by Type
  1. 4.1 Viral Conjunctivitis Drugs Type Introduction
  2. 4.1.1 FST-100
  3. 4.1.2 APD—209
  4. 4.2 Global Viral Conjunctivitis Drugs Sales Value by Type
  5. 4.2.1 Global Viral Conjunctivitis Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Viral Conjunctivitis Drugs Sales Value by Type (2021-2032)
  7. 4.2.3 Global Viral Conjunctivitis Drugs Sales Value Share by Type (2021-2032)
5 Viral Conjunctivitis Drugs Market by Application
  1. 5.1 Viral Conjunctivitis Drugs Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 ASCs
  4. 5.1.3 Others
  5. 5.2 Global Viral Conjunctivitis Drugs Sales Value by Application
  6. 5.2.1 Global Viral Conjunctivitis Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Viral Conjunctivitis Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Viral Conjunctivitis Drugs Sales Value Share by Application (2021-2032)
6 Viral Conjunctivitis Drugs Regional Value Analysis
  1. 6.1 Global Viral Conjunctivitis Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Viral Conjunctivitis Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Viral Conjunctivitis Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Viral Conjunctivitis Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Viral Conjunctivitis Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Viral Conjunctivitis Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Viral Conjunctivitis Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Viral Conjunctivitis Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Viral Conjunctivitis Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Viral Conjunctivitis Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Viral Conjunctivitis Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Viral Conjunctivitis Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Viral Conjunctivitis Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Viral Conjunctivitis Drugs Sales Value Share by Country, 2025 VS 2032
7 Viral Conjunctivitis Drugs Country-level Value Analysis
  1. 7.1 Global Viral Conjunctivitis Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Viral Conjunctivitis Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Viral Conjunctivitis Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Viral Conjunctivitis Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Viral Conjunctivitis Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Viral Conjunctivitis Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Viral Conjunctivitis Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Viral Conjunctivitis Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Viral Conjunctivitis Drugs Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Viral Conjunctivitis Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Viral Conjunctivitis Drugs Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Panoptes Pharma
  14. 8.3.1 Panoptes Pharma Company Information
  15. 8.3.2 Panoptes Pharma Business Overview
  16. 8.3.3 Panoptes Pharma Viral Conjunctivitis Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Panoptes Pharma Viral Conjunctivitis Drugs Product Portfolio
  18. 8.3.5 Panoptes Pharma Recent Developments
  19. 8.4 NovaBay Pharmaceuticals
  20. 8.4.1 NovaBay Pharmaceuticals Company Information
  21. 8.4.2 NovaBay Pharmaceuticals Business Overview
  22. 8.4.3 NovaBay Pharmaceuticals Viral Conjunctivitis Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 NovaBay Pharmaceuticals Viral Conjunctivitis Drugs Product Portfolio
  24. 8.4.5 NovaBay Pharmaceuticals Recent Developments
  25. 8.5 NicOx
  26. 8.5.1 NicOx Company Information
  27. 8.5.2 NicOx Business Overview
  28. 8.5.3 NicOx Viral Conjunctivitis Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 NicOx Viral Conjunctivitis Drugs Product Portfolio
  30. 8.5.5 NicOx Recent Developments
  31. 8.6 NanoViricides
  32. 8.6.1 NanoViricides Company Information
  33. 8.6.2 NanoViricides Business Overview
  34. 8.6.3 NanoViricides Viral Conjunctivitis Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 NanoViricides Viral Conjunctivitis Drugs Product Portfolio
  36. 8.6.5 NanoViricides Recent Developments
  37. 8.7 Allergan
  38. 8.7.1 Allergan Company Information
  39. 8.7.2 Allergan Business Overview
  40. 8.7.3 Allergan Viral Conjunctivitis Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Allergan Viral Conjunctivitis Drugs Product Portfolio
  42. 8.7.5 Allergan Recent Developments
  43. 8.8 Adenovir Pharma
  44. 8.8.1 Adenovir Pharma Company Information
  45. 8.8.2 Adenovir Pharma Business Overview
  46. 8.8.3 Adenovir Pharma Viral Conjunctivitis Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Adenovir Pharma Viral Conjunctivitis Drugs Product Portfolio
  48. 8.8.5 Adenovir Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst